The Role of F-18 FDG PET within Randomized Multicenter Phase III Trials for Multimodality Treatment of Non-Small Cell Lung Cancer Stage III
M Schmuecking, CP Schneider, RP Baum, M Scheithauer, N Presselt, J Leonhardi, TG Wendt, KM Mueller, R Bonnet · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · 2007 · Heft 05
Bibliografische Angaben
Zusammenfassung
Ziele: To evaluate the role of F-18 FDG PET) within clinical trials for staging, therapy management, molecular radiation treatment planning (MRTP) and early therapy response after neoadjuvant chemoradiation and its effect on survival as compared to histopathologic tumor response (regression grade), findings in 156 patients with non-small cell lung cancer (NSCLC) stage III are analyzed prospectively in a randomized, multicenter phase III trial. Methode: Neoadjuvant treatment: 2–3 cycles of paclitaxel/carboplatin and a block of chemoradiation. Staging: pretherapeutic PET scan in addition to spiral CT and/or MRI af…